Drug and Therapeutics Bulletin 1998;36:60-61; doi:10.1136/dtb.1998.36860
Copyright © 1998 by the BMJ Publishing Group Ltd.

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Donepezil update

Relevant BNF section: 4.11

In October 1997, we reviewed donepezil (Aricept-Eisai; Pfizer) as a new treatment for Alzheimer's disease and, on the evidence available, could not recommend its use. We argued that the position would change if more tangible evidence became available showing that the product offers real improvement in patients' wellbeing.¹ Since then, the results of two more randomised controlled trials have been published,^2,3 as has a long-term follow-up study of participants in the original study.^4,5 Here we review our position, taking into account these new data.

This article has been cited by other articles:

				Y. Doyle Equity in the new NHS: hard lessons from implementing a local healthcare policy on donepezil BMJ, July 28, 2001; 323(7306): 222 - 224. [Full Text] [PDF]